NeuronScore
Signal quality across funding, news, traction & verificationAbout Anagram Therapeutics
Anagram Therapeutics is a biopharmaceutical company focused on creating breakthrough orally delivered enzyme therapies for debilitating malabsorption syndromes and nutrient metabolism disorders. Their lead candidate, ANG003, is a novel broad-spectrum recombinant non-porcine enzyme replacement therapy currently in Phase 2 clinical trials for exocrine pancreatic insufficiency due to cystic fibrosis.
Funding History
1 round · $250M total| Date | Stage | Lead Investors | Amount |
|---|---|---|---|
| May 2024 | Other | Blackstone Life Sciences | $250M |
Pearl Health
80AI value-based care platform for primary care providers
OpenEvidence
60AI medical assistant for clinicians
Profluent
50Frontier AI models for programmable biology and protein design
Ambience Healthcare
46The AI operating system for healthcare
Suki AI
44AI voice assistant for clinicians
Recursion
38Pioneering AI-driven solutions in drug discovery to radically improve lives.
FAQ
How much funding has Anagram Therapeutics raised?
Anagram Therapeutics has raised $250M across 1 round — most recently a Other led by Blackstone Life Sciences in May 2024.
How much does Anagram Therapeutics cost?
Anagram Therapeutics pricing: Enterprise · Contact sales.
Discussion
Sign in to join the discussion.
Sign inExplore more around Anagram Therapeutics
Contextual paths to related AI startups, deals and rankings.